Molecular mechanisms of cisplatin resistance

Galluzzi, L; Senovilla, L; Vitale, I; Michels, J; Martins, I; Kepp, O; Castedo, M; Kroemer, G

doi:10.1038/onc.2011.384

Cited by 2,760Metal complexes synthesis and propertiesDNA Repair MechanismsCancer therapeutics and mechanisms

Molecular mechanisms of cisplatin resistance

Galluzzi, L, Senovilla, L, Vitale, I, Michels, J, Martins, I, Kepp, O, Castedo, M, Kroemer, G·2012·Oncogene

DOI 10.1038/onc.2011.384

Open this paper in CoChat — free account

Abstract

Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis. Despite a consistent rate of initial responses, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure. An intense research has been conducted during the past 30 years and several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have been described. Here, we provide a systematic discussion of these mechanism by classifying them in alterations (1) that involve steps preceding the binding of cisplatin to DNA (pre-target resistance), (2) that directly relate to DNA-cisplatin adducts (on-target resistance), (3) concerning the lethal signaling pathway(s) elicited by cisplatin-mediated DNA damage (post-target resistance) and (4) affecting molecular circuitries that do not present obvious links with cisplatin-elicited signals (off-target resistance). As in some clinical settings cisplatin constitutes the major therapeutic option, the development of chemosensitization strategies constitute a goal with important clinical implications.

Integrity signals

Registry

Crossref · 10.1038/onc.2011.384

Cites

193 of 193 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Constant or prolonged cisplatin treatment often results in acquisition of resistance through selection bias of alternative cell survival pathways, leading to therapeutic failure and poor prognosis.
“Also, constant or prolonged cisplatin treatment often results in the acquisition of resistance through the selection bias of alternative cell survival pathways, leading to therapeutic failure and poor prognosis [9, 10].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [9]
Cells can prevent cisplatin from reaching and harming DNA by reducing drug uptake, increasing drug efflux, and inactivating the drug through covalent binding to glutathione or metalloproteins.
“Mechanistically, cells can prevent cisplatin from reaching and harming DNA by reducing drug uptake, increasing drug efflux, and inactivating the drug through covalent binding to glutathione or metalloproteins [9, 10].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [9]
Mitotic catastrophe is a major mechanism of action of anticancer chemotherapeutics, reflecting increased resistance of neoplastic cells to intrinsic apoptosis.
“However, mitotic catastrophe appears to constitute a major mechanism of action of anticancer chemotherapeutics, mostly reflecting the increased resistance of neoplastic cells to the induction of intrinsic apoptosis [1004–1009].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [1007]

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817 · see citing works
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · see citing works
The resurgence of platinum-based cancer chemotherapy
Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733 · see citing works
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · see citing works
Mitochondrial membrane permeabilization in cell death
Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598 · see citing works
Self-citation
Autophagy and the Integrated Stress Response
Kroemer, G., Mariño, G., & Levine, B. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.023 · Cited by 3,506 · see citing works
Self-citation
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335 · see citing works
Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints
Sancar, A., Lindsey-Boltz, L. A., Ünsal-Kaçmaz, K., & Linn, S. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073723 · Cited by 3,317 · see citing works
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · see citing works
Self-citation
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,953 · see citing works
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626 · see citing works
p53 in health and disease
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,275 · see citing works
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B., Pitot, H. C., & Alberts, S. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,251 · see citing works
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004 · see citing works
A family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · see citing works
DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
Olaussen, K. A., Dunant, A., Fouret, P. J., Brambilla, E. M., André, F., Haddad, V., Clermont, E., Filipits, M., Pirker, R., Popper, H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,725 · see citing works
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713 · see citing works
Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer
Giacchetti, S., Perpoint, B., Zidani, R., Bail, N. L., Faggiuolo, R., Focan, C., Chollet, P. J. M., Llory, J., Letourneau, Y., Coudert, B. P., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,404 · see citing works
DNA MISMATCH REPAIR
Kunkel, T. A., & Erie, D. A. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133243 · Cited by 1,372 · see citing works
The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
Smith, J., Tho, L. M., Xu, N., & Gillespie, D. A. (2010) · Advances in cancer research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,279 · see citing works
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesnière, A., Schlemmer, F., Boige, V., Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apétoh, L., Barault, L., et al. (2009) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,177 · see citing works
Self-citation
Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells
Zhou, B. P., Liao, Y., Xia, W., Spohn, B., Lee, M., & Hung, M. (2001) · Nature Cell Biology · doi:10.1038/35060032 · Cited by 1,135 · see citing works
ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1
Zhao, H., & Piwnica-Worms, H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.13.4129-4139.2001 · Cited by 1,091 · see citing works
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086 · see citing works
Post‐translational modifications and activation of p53 by genotoxic stresses
Appella, E., & Anderson, C. W. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02225.x · Cited by 1,071 · see citing works
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011 · see citing works
Survivin, cancer networks and pathway-directed drug discovery
Altieri, D. C. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2293 · Cited by 998 · see citing works
The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites.
Shieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972 · see citing works
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967 · see citing works
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927 · see citing works
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867 · see citing works
Mitotic catastrophe: a mechanism for avoiding genomic instability
Vitale, I., Galluzzi, L., Castedo, M., & Kroemer, G. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3115 · Cited by 834 · see citing works
Self-citation
Clinical development of platinum complexes in cancer therapy: an historical perspective and an update
Lebwohl, D., & Canetta, R. M. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00224-x · Cited by 756 · see citing works
Requirement for ERK Activation in Cisplatin-induced Apoptosis
Wang, X., Martindale, J. L., & Holbrook, N. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004583200 · Cited by 678 · see citing works
Drug Resistance and ATP-Dependent Conjugate Transport Mediated by the Apical Multidrug Resistance Protein, MRP2, Permanently Expressed in Human and Canine Cells
Cui, Y., König, J., Buchholz, U., Spring, H., Leier, I., & KEPPLER, D. O. R. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23190-4 · Cited by 674 · see citing works
The ATP-dependent glutathione S-conjugate export pump
Ishikawa, T. (1992) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(92)90489-v · Cited by 658 · see citing works
Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial
Rothenberg, M. L., Oza, A. M., Bigelow, R., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., Hart, L. L., Gupta, S., Garay, C. A., Burger, B., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.126 · Cited by 646 · see citing works
Molecular Mechanisms of Mammalian Global Genome Nucleotide Excision Repair
Gillet, L. C. J., & Schärer, O. D. (2006) · Chemical Reviews · doi:10.1021/cr040483f · Cited by 642 · cited 1× · see citing works
“In this setting, damaged nucleotides are excised from DNA upon incision on both sides of the lesion, followed by DNA synthesis to reconstitute genetic integrity (Gillet and Scharer, 2006).”
Interactions of Antitumor Metallodrugs with Serum Proteins: Advances in Characterization Using Modern Analytical Methodology
Timerbaev, A. R., Hartinger, C. G., Aleksenko, S. S., & Keppler, B. K. (2006) · Chemical Reviews · doi:10.1021/cr040704h · Cited by 615 · see citing works
Cisplatin: From DNA damage to cancer chemotherapy
Cohen, S. M., & Lippard, S. J. (2001) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(01)67026-0 · Cited by 614 · see citing works
ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy
Shirota, Y., Stoehlmacher, J., Brabender, J., Xiong, Y.-P., Uetake, H., Danenberg, K. D., Groshen, S. G., Tsao-Wei, D. D., Danenberg, P. V., & Lenz, H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.23.4298 · Cited by 611 · see citing works
Overexpression of Metallothionein Confers Resistance to Anticancer Drugs
Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H., & Lazo, J. S. (1988) · Science · doi:10.1126/science.3175622 · Cited by 601 · see citing works
Is Cisplatin-Induced Cell Death Always Produced by Apoptosis?
González, V. M., Fuertes, M. A., Alonso‐Moreno, C., & Pérez, J. M. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.4.657 · Cited by 579 · see citing works
Xeroderma Pigmentosum Group F Caused by a Defect in a Structure-Specific DNA Repair Endonuclease
Sijbers, A. M., de Laat, W. L., Ariza, R. R., Biggerstaff, M., Wei, Y.-F., Moggs, J. G., Carter, K. C., Shell, B. K., Evans, E. L., de Jong, M. C., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)80155-5 · Cited by 546 · see citing works
The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes
Eastman, A. R. (1987) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(87)90009-x · Cited by 542 · see citing works
Cisplatin Induces Endoplasmic Reticulum Stress and Nucleus-independent Apoptotic Signaling
Mandic, A., Hansson, J., Linder, S. T., & Shoshan, M. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210284200 · Cited by 509 · see citing works
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.
Metzger, R., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Lenz, H.-J., Hayashi, K., Groshen, S. G., Salonga, D. S., Cohen, H., Laine, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.309 · Cited by 505 · see citing works
Loss of DNA mismatch repair in acquired resistance to cisplatin.
Aebi, S. P., Kurdi-Haidar, B., Gordon, R. T., Cenni, B., Zheng, H., Fink, D. A., Christen, R. D., Boland, C. R., Koi, M., Fishel, R. A., et al. (1996) · PubMed · Cited by 502 · see citing works
The Structure-Specific Endonuclease Ercc1-Xpf Is Required To Resolve DNA Interstrand Cross-Link-Induced Double-Strand Breaks
Niedernhofer, L. J., Odijk, H., Budzowska, M., van Drunen, E., Maas, A., Theil, A. F., de Wit, J., Jaspers, N. G. J., Beverloo, H. B., Hoeijmakers, J. H. J., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5776-5787.2004 · Cited by 493 · see citing works
The role of DNA mismatch repair in drug resistance
Nebel, S. (1998) · ETH Zürich Research Collection · doi:10.3929/ethz-a-001915508 · Cited by 465 · see citing works
Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress
Martins, I., Kepp, O., Schlemmer, F., Adjemian, S., Tailler, M., Shen, S., Michaud, M., Menger, L., Gdoura, A., Tajeddine, N., et al. (2010) · Oncogene · doi:10.1038/onc.2010.500 · Cited by 414 · see citing works
Self-citation
Cisplatin (cis-diamminedichloroplatinum II)
Prestayko, A. W., D'Aoust, J. C., Issell, B. F., & Crooke, S. T. (1979) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(79)80057-2 · Cited by 405 · see citing works
Survivin: A new target for anti-cancer therapy
Ryan, B. M., O’Donovan, N., & Duffy, M. J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.05.003 · Cited by 378 · see citing works
Sustained Activation of JNK/p38 MAPK Pathways in Response to Cisplatin Leads to Fas Ligand Induction and Cell Death in Ovarian Carcinoma Cells
Mansouri, A., Ridgway, L. D., Korapati, A. L., Zhang, Q. C., Tian, L., Wang, Y., Siddik, Z. H., Mills, G. B., & Claret, F. X. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208134200 · Cited by 377 · see citing works
Medical Treatment of Advanced Testicular Cancer
Feldman, D. R. (2008) · JAMA · doi:10.1001/jama.299.6.672 · Cited by 374 · see citing works
Clinical Perspectives on Platinum Resistance
Giaccone, G. (2000) · Drugs · doi:10.2165/00003495-200059004-00002 · Cited by 364 · see citing works
Cisplatin resistance: Preclinical findings and clinical implications
Köberle, B., Tomicic, M. T., Usanova, S., & Kaina, B. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.07.004 · Cited by 361 · see citing works
Increased Expression of the Copper Efflux Transporter ATP7A Mediates Resistance to Cisplatin, Carboplatin, and Oxaliplatin in Ovarian Cancer Cells
Samimi, G., Safaei, R., Katano, K., Holzer, A. K., Rochdi, M., Tomioka, M., Goodman, M., & Howell, S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0137 · Cited by 357 · see citing works
Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells.
Furuta, T., Ueda, T., Aune, G. J., Sarasin, A. R., Kraemer, K. H., & Pommier, Y. G. (2002) · PubMed · Cited by 349 · see citing works
Contribution of the Major Copper Influx Transporter CTR1 to the Cellular Accumulation of Cisplatin, Carboplatin, and Oxaliplatin
Holzer, A. K., Manorek, G., & Howell, S. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022624 · Cited by 323 · see citing works
Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer
Chetrit, A., Hirsh‐Yechezkel, G., Ben‐David, Y., Lubin, F., Friedman, E., & Sadetzki, S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6905 · Cited by 323 · see citing works
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
Joaquim Bellmunt, B., Paz-Ares, L. G., Cuello, M., Cecere, F. L., Albiol, S., Guillém, V., Gallardo, E., Carles, J., Méndez, P., de la Cruz, J. J., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl435 · Cited by 319 · see citing works
Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide- binding Pocket
Donnelly, A. C., & Blagg, B. S. J. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786242895 · Cited by 314 · see citing works
ATR-Chk2 Signaling in p53 Activation and DNA Damage Response during Cisplatin-induced Apoptosis
Pabla, N., Huang, S., Mi, Q.-S., Daniel, R., & Dong, Z. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707568200 · Cited by 309 · see citing works
ERCC1 and ERCC2 Expression in Malignant Tissues From Ovarian Cancer Patients
Dabholkar, M., Bostick-Bruton, F., Weber, C., Bohr, V. A., Egwuagu, C. E., & Reed, E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.19.1512 · Cited by 305 · see citing works
Tumor-suppressor p53: implications for tumor development and prognosis.
Kirsch, D. G., & Kastan, M. B. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3158 · Cited by 301 · see citing works
ERCC1-XPF Endonuclease Facilitates DNA Double-Strand Break Repair
Ahmad, A., Robinson, A. R., Duensing, A. U., van Drunen, E., Beverloo, H. B., Weisberg, D. B., Hasty, P., Hoeijmakers, J. H. J., & Niedernhofer, L. J. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00293-08 · Cited by 298 · see citing works
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Kepp, O., Galluzzi, L., Martins, I., Schlemmer, F., Adjemian, S., Michaud, M., Sukkurwala, A. Q., Menger, L., Zitvogel, L., & Kroemer, G. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9273-4 · Cited by 296 · see citing works
Self-citation
Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line
Drummond, J. T., Anthoney, A., Brown, R. E., & Modrich, P. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19645 · Cited by 295 · see citing works
The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman, A., Varchenko, M., Umar, A., Kunkel, T. A., Risinger, J. I., Barrett, J. C., Hamilton, T. C., & Chaney, S. G. (1998) · PubMed · Cited by 294 · see citing works
DNA unwinding produced by site-specific intrastrand crosslinks of the antitumor drug cis-diamminedichloroplatinum(II)
Bellon, S. F., Coleman, J. H., & Lippard, S. J. (1991) · Biochemistry · doi:10.1021/bi00246a021 · Cited by 293 · see citing works
Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.
Katano, K., Kondo, A., Safaei, R., Holzer, A. K., Samimi, G., Mishima, M., Kuo, Y., Rochdi, M., & Howell, S. B. (2002) · PubMed · Cited by 290 · see citing works
Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator
Ishida, S., McCormick, F. P., Smith‐McCune, K., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.011 · Cited by 290 · see citing works
Effect of Extracellular Signal-regulated Kinase on p53 Accumulation in Response to Cisplatin
Persons, D. L., Yazlovitskaya, E. M., & Pelling, J. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004267200 · Cited by 288 · see citing works
Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology
Ratnam, K., & Low, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2260 · Cited by 286 · see citing works
Two-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals
Shachar, S., Ziv, O., Avkin, S., Adar, S., Wittschieben, J., Reißner, T., Chaney, S., Friedberg, E. C., Wang, Z., Carell, T., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2008.281 · Cited by 284 · see citing works
Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy
Chen, H. H. W., & Kuo, M. T. (2010) · Metal-Based Drugs · doi:10.1155/2010/430939 · Cited by 284 · see citing works
Preclinical Perspectives on Platinum Resistance
Kèlland, L. R. (2000) · Drugs · doi:10.2165/00003495-200059004-00001 · Cited by 280 · see citing works
Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology
Shuck, S. C., Short, E. A., & Turchi, J. J. (2008) · Cell Research · doi:10.1038/cr.2008.2 · Cited by 279 · see citing works
DNA Repair: Enzymatic Mechanisms and Relevance to Drug Response
Chaney, S. G., & Sancar, A. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.19.1346 · Cited by 279 · see citing works
Cisplatin Preferentially Binds Mitochondrial DNA and Voltage-Dependent Anion Channel Protein in the Mitochondrial Membrane of Head and Neck Squamous Cell Carcinoma: Possible Role in Apoptosis
Yang, Z., Schumaker, L. M., Egorin, M. J., Zuhowski, E. G., Guo, Z., & Cullen, K. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1037 · Cited by 270 · see citing works
The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients
Gifford, G., Paul, J., Vasey, P. A., Kaye, S. B., & Brown, R. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0732 · Cited by 262 · see citing works
Preclinical studies identifying carboplatin as a viable cisplatin alternative
Harrap, K. R. (1985) · Cancer Treatment Reviews · doi:10.1016/0305-7372(85)90015-5 · Cited by 259 · see citing works
Adriamycin cardiomyopathy—risk factors
Minow, R. A., Benjamin, R. S., Lee, E. T., & Gottlieb, J. A. (1977) · Cancer · doi:10.1002/1097-0142(197704)39:4 · Cited by 252 · see citing works
A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells.
Koike, K., Kawabe, T., Tanaka, T., Toh, S., Uchiumi, T., Wada, M., Akiyama, S. I., Ono, M., & Kuwano, M. (1997) · PubMed · Cited by 249 · see citing works
hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents
Brown, R. E., Hirst, G. L., Gallagher, W. M., McIlwrath, A. J., Margison, G. P., van der Zee, A. G., & Anthoney, A. (1997) · Oncogene · doi:10.1038/sj.onc.1201167 · Cited by 243 · see citing works
Antitumor activity of 1,2-diaminocyclohexaneplatinum complexes against Sarcoma-180 ascites form
Kidani, Y., Kenji Inagaki, Z., Iigo, M., Hoshi, A., & Kuretani, K. (1978) · Journal of Medicinal Chemistry · doi:10.1021/jm00210a029 · Cited by 239 · see citing works
Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin
Division, P. (1992) · Lung Cancer · doi:10.1016/0169-5002(92)90185-m · Cited by 238 · see citing works
Effect of BRCA mutations on the length of survival in epithelial ovarian tumors.
David, Y. B., Chetrit, A., Hirsh-Yechezkel, G., Friedman, E., Beck, B. D., Beller, U., Ben-Baruch, G., Fishman, A., Levavi, H., Lubin, F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.463 · Cited by 224 · see citing works
Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kèlland, L. R., Abel, G., McKeage, M. J., Jones, M., Goddard, P. M., Valenti, M., Murrer, B. A., & Harrap, K. R. (1993) · PubMed · Cited by 224 · see citing works
Recent Developments in the Field of Anticancer Platinum Complexes
Galanski, M. S. (2006) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489206777442287 · Cited by 223 · see citing works
Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects
Lewis, A. D., Hayes, J. D., & Wolf, C. R. (1988) · Carcinogenesis · doi:10.1093/carcin/9.7.1283 · Cited by 223 · see citing works
The role of DNA mismatch repair in drug resistance.
Fink, D. A., Aebi, S. P., & Howell, S. B. (1998) · PubMed · Cited by 220 · see citing works
Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA
Berndtsson, M., Hägg, M., Panaretakis, T., Havelka, A. M., Shoshan, M. C., & Linder, S. T. (2006) · International Journal of Cancer · doi:10.1002/ijc.22132 · Cited by 216 · see citing works
Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death
Tajeddine, N., Galluzzi, L., Kepp, O., Hangen, E., Morselli, E., Senovilla, L., Araujo, N., Pinna, G., Larochette, N., Zamzami, N., et al. (2008) · Oncogene · doi:10.1038/onc.2008.63 · Cited by 207 · see citing works
Self-citation
Apoptosis regulation in tetraploid cancer cells
Castedo, M., Coquelle, A., Vivet, S., Vitale, I., Kauffmann, A., Dessen, P., Péquignot, M. O., Casares, N., Valent, A., Mouhamad, S., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601127 · Cited by 206 · see citing works
Self-citation
Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance
Brozović, A., & Osmak, M. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.10.007 · Cited by 204 · see citing works
Bypass of DNA Lesions Generated During Anticancer Treatment with Cisplatin by DNA Polymerase η
Alt, A., Lammens, K., Chiocchini, C., Lammens, A., Pieck, J. C., Kuch, D., Hopfner, K., & Carell, T. (2007) · Science · doi:10.1126/science.1148242 · Cited by 204 · see citing works
The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin
Mello, J. A., Acharya, S., Fishel, R. A., & Essigmann, J. M. (1996) · Chemistry & Biology · doi:10.1016/s1074-5521(96)90149-0 · Cited by 198 · see citing works
Increased Gene-Specific Repair of Cisplatin Interstrand Cross-Links in Cisplatin-Resistant Human Ovarian Cancer Cell Lines
Zhen, W. K., Link, C. J., O'Connor, P. M., Reed, E., Parker, R., Howell, S. B., & Bohr, V. A. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.9.3689 · Cited by 196 · see citing works
Nitrone spin traps and a nitroxide antioxidant inhibit a common pathway of thymocyte apoptosis
Slater, A. F. G., Nobel, S., Maellaro, E., Bustamante, J., Kimland, M., & Orrenius, S. (1995) · Biochemical Journal · doi:10.1042/bj3060771 · Cited by 188 · see citing works
Role of the Copper Transporter, CTR1, in Platinum-Induced Ototoxicity
More, S. S., Akil, O., Ianculescu, A. G., Geier, E. G., Lustig, L. R., & Giacomini, K. M. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1544-10.2010 · Cited by 177 · see citing works
Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease
Williams, J. A. S., Lucas, P. C., Griffith, K. A., Choi, M., Fogoros, S. K., Hu, Y., & Liu, J. R. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.10.026 · Cited by 173 · see citing works
Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes
Loh, S. Y., Mistry, P., Kèlland, L. R., Abel, G., & Harrap, K. R. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.419 · Cited by 167 · see citing works
Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression
Usanova, S., Piée‐Staffa, A., Sied, U., Thomale, J., Schneider, A., Kaina, B., & Köberle, B. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-248 · Cited by 164 · see citing works
Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review
Stordal, B., Pavlakis, N., & Davey, R. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.01.009 · Cited by 162 · see citing works
Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.
Li, Q., Yu, J., Mu, C., Yunmbam, M. K., Slavsky, D., Cross, C. L., Bostick-Bruton, F., & Reed, E. (2000) · PubMed · Cited by 161 · see citing works
The structure‐specific endonuclease Ercc1—Xpf is required for targeted gene replacement in embryonic stem cells
Niedernhofer, L. J., Essers, J., Weeda, G., Beverloo, B., de Wit, J., Muijtjens, M., Odijk, H., Hoeijmakers, J. H. J., & Kanaar, R. (2001) · The EMBO Journal · doi:10.1093/emboj/20.22.6540 · Cited by 159 · see citing works
Mutations of the p53 gene do not occur in testis cancer.
Peng, H., Hogg, D., Malkin, D. M., Bailey, D., Gallie, B. L., Bulbul, M., Jewett, M. A. S., Buchanan, J., & Goss, P. E. (1993) · PubMed · Cited by 154 · see citing works
Altered ErbB Receptor Signaling and Gene Expression in Cisplatin-Resistant Ovarian Cancer
MacLeod, K. G., Mullen, P., Sewell, J. M., Rabiasz, G. J., Lawrie, S. S., Miller, E. P., Smyth, J. F., & Langdon, S. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2684 · Cited by 152 · see citing works
ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
Jun, H. J., Ahn, M., Kim, H. S., Yi, S. Y., Han, J., Lee, S. K., Ahn, Y. C., Jeong, H.-S., Son, Y.-I., Baek, J.-H., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604464 · Cited by 149 · see citing works
Bcl-2 Blocks Cisplatin-Induced Apoptosis and Predicts Poor Outcome Following Chemoradiation Treatment in Advanced Oropharyngeal Squamous Cell Carcinoma
Michaud, W. A., Nichols, A. C., Mroz, E. A., Faquin, W. C., Clark, J. R., Begum, S., Westra, W. H., Wada, H., Busse, P. M., Ellisen, L. W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2581 · Cited by 147 · see citing works
Long‐term activation of SAPK/JNK, p38 kinase and fas‐L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance
Brozović, A., Fritz, G., Christmann, M., Zisowsky, J., Jaehde, U., Osmak, M., & Kaina, B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20522 · Cited by 146 · see citing works
Copper‐transporting P‐type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: Comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP
Nakayama, K., Kanzaki, A., Ogawa, K., Miyazaki, K., Neamati, N., & Takebayashi, Y. (2002) · International Journal of Cancer · doi:10.1002/ijc.10608 · Cited by 145 · see citing works
Altered expression and mutation of β‐catenin gene in gastric carcinomas and cell lines
Woo, D. K., Kim, H. S., Lee, H. S., Kang, Y. H., Yang, H. K., & Kim, W. H. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010320)95:2 · Cited by 143 · see citing works
Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes
Eastman, A. R. (1987) · Chemico-Biological Interactions · doi:10.1016/0009-2797(87)90004-4 · Cited by 141 · see citing works
A Novel Epidermal Growth Factor Receptor Inhibitor Promotes Apoptosis in Non–Small Cell Lung Cancer Cells Resistant to Erlotinib
de La Motte Rouge, T., Galluzzi, L., Olaussen, K. A., Zermati, Y., Tasdemir, E., Robert, T., Ripoche, H., Lazar, V., Dessen, P., Harper, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0538 · Cited by 141 · see citing works
Self-citation
The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.
Mitsuuchi, Y., Johnson, S. W., Selvakumaran, M., Williams, S. J., Hamilton, T. C., & Testa, J. R. (2000) · PubMed · Cited by 137 · see citing works
Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NFκB activation
Yeh, P.-Y., Chuang, S., Yeh, K., Song, Y., Ea, C.-K., & Cheng, A. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00908-5 · Cited by 136 · see citing works
Excision Repair Cross Complementation Group 1 Immunohistochemical Expression Predicts Objective Response and Cancer-Specific Survival in Patients Treated by Cisplatin-Based Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Handra‐Luca, A., Hernandez, J., Mountzios, G., Clermont, E., Guily, J. L. S., Soria, J., & Fouret, P. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0252 · Cited by 135 · see citing works
The Internalization and Degradation of Human Copper Transporter 1 following Cisplatin Exposure
Holzer, A. K., & Howell, S. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1710 · Cited by 134 · see citing works
Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma
Yamasaki, M., Makino, T., Masuzawa, T., Kurokawa, Y., Miyata, H., Takiguchi, S., Nakajima, K., Fujiwara, Y., Matsuura, N., Mori, M., et al. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606071 · Cited by 130 · see citing works
Overexpression of cMOAT (MRP2/ABCC2) Is Associated with Decreased Formation of Platinum-DNA Adducts and Decreased G2-Arrest in Melanoma Cells Resistant to Cisplatin
Liedert, B., Materna, V., Schadendorf, D., Thomale, J., & Lage, H. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12313.x · Cited by 129 · see citing works
Loss of DNA Polymerase ζ Causes Chromosomal Instability in Mammalian Cells
Wittschieben, J. P., Reshmi, S. C., Gollin, S. M., & Wood, R. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2982 · Cited by 128 · see citing works
p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins
Yu, H., Su, J., Xu, Y., Kang, J., Li, H., Zhang, L., Yi, H., Xiang, X., Liu, F., & Sun, L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.01.019 · Cited by 127 · see citing works
Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells
Branch, P., Masson, M., Aquilina, G., Bignami, M., & Karran, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203668 · Cited by 126 · see citing works
Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors
David, Y. B., Chetrit, A., Hirsh‐Yechezkel, G., Friedman, E., Beck, B. D., Beller, U., Ben‐Baruch, G., Fishman, A., Levavi, H., Lubin, F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.2.463 · Cited by 126 · see citing works
Reversal of Multidrug Resistance by Natural Substances from Plants
Wang, Q., Michalak, K., Wesołowska, O., Deli, J., Molnár, P., Hohmann, J., Molnar, J. A., & Engi, H. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610792928103 · Cited by 124 · see citing works
Overexpression of N-methylpurine-DNA glycosylase in Chinese hamster ovary cells renders them more sensitive to the production of chromosomal aberrations by methylating agents — a case of imbalanced DNA repair
Coquerelle, T. M., Dösch, J., & Kaina, B. (1995) · Mutation Research/DNA Repair · doi:10.1016/0921-8777(94)00035-5 · Cited by 123 · see citing works
Acquired Cisplatin Resistance in Human Lung Adenocarcinoma Cells Is Associated with Enhanced Autophagy
Ren, J., He, W., Nong, L., Zhu, Q., Hu, K., Zhang, R., Huang, L., Zhu, F., & Wu, G. (2010) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0701 · Cited by 123 · see citing works
Cisplatin Induction of ERCC-1 mRNA Expression in A2780/CP70 Human Ovarian Cancer Cells
Li, Q., Gardner, K. L., Zhang, L., Tsang, B., Bostick-Bruton, F., & Reed, E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.36.23419 · Cited by 120 · see citing works
The role of copper transporters in the development of resistance to Pt drugs
Safaei, R., Holzer, A. K., Katano, K., Samimi, G., & Howell, S. B. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.05.006 · Cited by 114 · see citing works
Prognostic Value of the Cu-Transporting ATPase in Ovarian Carcinoma Patients Receiving Cisplatin-Based Chemotherapy
Nakayama, K., Kanzaki, A., Terada, K., Mutoh, M., Ogawa, K., Sugiyama, T., Takenoshita, S., Itoh, K., Yaegashi, N., Miyazaki, K., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0454 · Cited by 114 · see citing works
In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin
Mellish, K. J., Kelland, L., & Harrap, K. R. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.322 · Cited by 113 · see citing works
Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray.
Sakamoto, M., Kondo, A., Kawasaki, K., Goto, T., Sakamoto, H., Miyake, K., Koyamatsu, Y., Akiya, T., Iwabuchi, H., Muroya, T., et al. (2001) · PubMed · Cited by 110 · see citing works
Mutagenic and carcinogenic properties of platinum-based anticancer drugs
Sanderson, B. J. S., Ferguson, L. R., & Denny, W. A. (1996) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(96)00022-x · Cited by 109 · see citing works
Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer
Hengstler, J. G., Lange, J., Kett, A., Dornhöfer, N., Meinert, R., Arand, M., Knapstein, P. G., Becker, R., Oesch, F., & Tanner, B. (1999) · PubMed · doi:10.5167/uzh-113865 · Cited by 106 · see citing works
Down-regulation of Mammalian Sterile 20–Like Kinase 1 by Heat Shock Protein 70 Mediates Cisplatin Resistance in Prostate Cancer Cells
Ren, A., Yan, G., You, B., & Sun, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6248 · Cited by 106 · see citing works
MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer
for the International Adjuvant Lung Trial-Bio investigators, Kamal, N. S., Soria, J., Mendiboure, J., Planchard, D., Olaussen, K. A., Rousseau, V., Popper, H., Pirker, R., Bertrand, P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2204 · Cited by 103 · see citing works
P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.
Baekelandt, M. M. O., Holm, R., Nesland, J. M., Trope, C. G., & Kristensen, G. B. (2000) · PubMed · Cited by 102 · see citing works
Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma
Wakai (2010) · Oncology Reports · doi:10.3892/or_00000721 · Cited by 99 · see citing works
Polymerase η mRNA Expression Predicts Survival of Non–Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
Ceppi, P., Novello, S., Cambieri, A., Longo, M., Monica, V., Iacono, M. L., Levra, M. G., Saviozzi, S., Volante, M., Papotti, M. G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1227 · Cited by 98 · see citing works
Mirk/Dyrk1B Maintains the Viability of Quiescent Pancreatic Cancer Cells by Reducing Levels of Reactive Oxygen Species
Deng, X., Ewton, D. Z., & Friedman, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2903 · Cited by 92 · see citing works
Cisplatinum and Taxol Induce Different Patterns of p53 Phosphorylation
Damia, G. L. M., Filiberti, L., Vikhanskaya, F., Carrassa, L., Taya, Y., D’Incalci, M., & Broggini, M. (2001) · Neoplasia · doi:10.1038/sj.neo.7900122 · Cited by 92 · see citing works
Phase II Study of Picoplatin As Second-Line Therapy for Patients With Small-Cell Lung Cancer
Eckardt, J. R., Bentsion, D., Lipatov, O. N., Polyakov, I. S., MacKintosh, F. R., Karlin, D. A., Baker, G. S., & Breitz, H. B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3235 · Cited by 92 · see citing works
Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype
Gourley, C., Michie, C. O., Roxburgh, P., Yap, T. A., Harden, S., Paul, J., Ragupathy, K., Todd, R., Petty, R., Reed, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1082 · Cited by 88 · see citing works
Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action.
Dent, P., & Grant, S. (2001) · PubMed · Cited by 88 · see citing works
Satraplatin: an orally available platinum analog for the treatment of cancer
Choy, H. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.7.973 · Cited by 85 · see citing works
Reactions of cisplatin hydrolytes with methionine, cysteine, and plasma ultrafiltrate studied by a combination of HPLC and NMR techniques
El-Khateeb, M., Appleton, T. G., Gahan, L. R., Charles, B. G., Berners‐Price, S. J., & Bolton, A.-M. (1999) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(99)00146-4 · Cited by 84 · see citing works
Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance
Yamamoto, K., Okamoto, A., Isonishi, S., Ochiai, K., & Ohtake, Y. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00532-8 · Cited by 81 · see citing works
Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine
Jin, J., Wang, F., Wei, H., & Liu, G.-T. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0868-0 · Cited by 80 · see citing works
Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs
Michalke, B. (2010) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2010.01.006 · Cited by 78 · see citing works
Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway
Vitale, I., Galluzzi, L., Vivet, S., Nanty, L., Dessen, P., Senovilla, L., Olaussen, K. A., Lazar, V., Prudhomme, M., Golsteyn, R. M., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001337 · Cited by 77 · see citing works
Self-citation
Mirk/Dyrk1B in cancer
Friedman, E. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21451 · Cited by 77 · see citing works
Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment
Wang, Y., Nangia‐Makker, P., Balan, V., Hogan, V. A., & Raz, A. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.79 · Cited by 77 · see citing works
Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications.
Gadducci, A., Cosio, S., Muraca, S., & Genazzani, A. R. (2002) · PubMed · Cited by 75 · see citing works
Mitochondrial Liaisons of p53
Galluzzi, L., Morselli, E., Kepp, O., Vitale, I., Pinti, M., & Kroemer, G. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3504 · Cited by 74 · see citing works
Self-citation
REV3L confers chemoresistance to cisplatin in human gliomas: The potential of its RNAi for synergistic therapy
Wang, H., Zhang, S., Wang, S., Lü, J., Wu, W., Weng, L., Chen, D., Zhang, Y., Lu, Z., Yang, H. J., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-015 · Cited by 74 · see citing works
A cyclopalladated complex interacts with mitochondrial membrane thiol-groups and induces the apoptotic intrinsic pathway in murine and cisplatin-resistant human tumor cells
Serrano, F. A., Matsuo, A. L., Monteforte, P. T., Bechara, A. H. S., Smaili, S. S., Santana, D. P., Rodrigues, T., Pereira, F. V., Silva, L. S., Machado, J., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-296 · Cited by 71 · see citing works
Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma
Aida, T., Takebayashi, Y., Shimizu, T., Okamura, C., Higasimoto, M., Kanzaki, A., Nakayama, K., Terada, K., Sugiyama, T., Miyazaki, K., et al. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.12.042 · Cited by 68 · see citing works
Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line
Spierings, D. C. J., de Vries, E. G. E., Vellenga, E., & de Jong, S. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401248 · Cited by 67 · see citing works
Ovarian cancer: new clinical approaches
Ozols, R. F. (1991) · Cancer Treatment Reviews · doi:10.1016/0305-7372(91)90027-w · Cited by 66 · see citing works
Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells
Gao, J., Zheng, Z., Rawal, B., Schell, M. J., Bepler, G., & Haura, E. B. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.17.9322 · Cited by 65 · see citing works
DNA Damage Recognition and Nucleotide Excision Repair in Mammalian CellsPreprint
Wood, R. D., Araújo, S. J., Ariza, R. R., Batty, D. P., Biggerstaff, M., Evans, E. L., Gaillard, P.-H. L., Gunz, D., Köberle, B., Kuraoka, I., et al. (2000) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2000.65.173 · Cited by 65 · see citing works
Survivin as a predictor of cis‐diamminedichloroplatinum sensitivity in gastric cancer patients
Nakamura, M., Tsuji, N., Asanuma, K., Kobayashi, D., Yagihashi, A., Hirata, K., Torigoe, T., Sato, N., & Watanabe, N. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03169.x · Cited by 63 · see citing works
Heat Shock Protein 27 Protects L929 Cells from Cisplatin-Induced Apoptosis by Enhancing Akt Activation and Abating Suppression of Thioredoxin Reductase Activity
Zhang, Y., & Shen, X. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2090 · Cited by 60 · see citing works
The Translesion Polymerase Rev3L in the Tolerance of Alkylating Anticancer Drugs
Roos, W. P., Tsaalbi‐Shtylik, A., Tsaryk, R., Güvercin, F., de Wind, N., & Kaina, B. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.058131 · Cited by 52 · see citing works
Caspase-mediated cleavage of ATM during cisplatin-induced tubular cell apoptosis: inactivation of its kinase activity toward p53
Wang, J., Pabla, N., Wang, C., Wang, W., Schoenlein, P. V., & Dong, Z. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00509.2005 · Cited by 52 · see citing works
c-Abl phosphorylation of ΔNp63α is critical for cell viability
Yuan, M., Luong, P., Hudson, C., Gudmundsdottir, K. K., & Basu, S. (2010) · Cell Death and Disease · doi:10.1038/cddis.2009.15 · Cited by 52 · see citing works
Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damaging agents.
Bramson, J. L., & Panasci, L. (1993) · PubMed · Cited by 51 · see citing works
Scytophycins, novel microfilament-depolymerizing agents which circumvent P-glycoprotein-mediated multidrug resistance.
Smith, C. D., Carmeli, S., MOORE, R. E., & Patterson, G. M. L. (1993) · PubMed · Cited by 50 · see citing works
The role of XAF1 in cancer.
Plenchette, S., Cheung, H. H., Fong, W. G., LaCasse, E. C., & Korneluk, R. G. (2007) · PubMed · Cited by 50 · see citing works
Death Receptor 5 and Bcl-2 Protein Expression as Predictors of Tumor Response to Gemcitabine and Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer
Han, J., Hong, E. K., Choi, B. G., Park, J. N., Kim, K. W., Kang, J., Jin, J., Park, S. Y., Hong, Y. S., & Lee, K. S. (2003) · Medical Oncology · doi:10.1385/mo:20:4:355 · Cited by 49 · see citing works
Patients with ERCC1-Negative Locally Advanced Esophageal Cancers May Benefit from Preoperative Chemoradiotherapy
Kim, M. K., Cho, K.-J., Kwon, G. Y., Park, S.-I., Kim, Y., Kim, J. H., Song, H.-Y., Shin, J. H., Jung, H., Lee, G. H., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4848 · Cited by 48 · see citing works
Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance
Shen, D., Ma, J., Okabe, M., Zhang, G., Xia, D., & Gottesman, M. M. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22287 · Cited by 47 · see citing works
Frameshifts and deletions during in vitro translesion synthesis past Pt–DNA adducts by DNA polymerases β and η
Bassett, E., Vaisman, A., Leeman, K. T., McCall, C. M., Masutani, C., Hanaoka, F., & Chaney, S. G. (2002) · DNA repair · doi:10.1016/s1568-7864(02)00150-7 · Cited by 45 · see citing works
Oxaliplatin in First-line Therapy for Advanced Non–Small-Cell Lung Cancer
Raez, L. E., Kobina, S., & Santos, E. S. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.003 · Cited by 42 · see citing works
Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer
Ikeguchi, M., & Kaibara, N. (2001) · International Journal of Molecular Medicine · doi:10.3892/ijmm.8.6.661 · Cited by 41 · see citing works
The Molecular Basis of Synergism between Carboplatin and ABT-737 Therapy Targeting Ovarian Carcinomas
Jain, H. V., & Meyer‐Hermann, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-3174 · Cited by 41 · see citing works
Mcl-1, Vascular Endothelial Growth Factor-R2, and 14-3-3σ Expression Might Predict Primary Response against Radiotherapy and Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Erović, B. M., Pelzmann, M., Grasl, M. C., Johannes, P., Kornek, G. V., Brannath, W., Selzer, E., & Thurnher, D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1170 · Cited by 39 · see citing works
Depleting Mirk Kinase Increases Cisplatin Toxicity in Ovarian Cancer Cells
Hu, J., & Friedman, E. (2010) · Genes & Cancer · doi:10.1177/1947601910377644 · Cited by 39 · see citing works
Requirement for ERCC-1 and ERCC-3 gene products in DNA excision repair in vitro. Complementation using rodent and human cell extracts.
Biggerstaff, M., & Wood, R. D. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50510-5 · Cited by 36 · see citing works
Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma.
Miyazaki, T., Kato, H., Faried, A., Sohda, M., Nakajima, M., Fukai, Y., Masuda, N., Manda, R., Fukuchi, M., Ojima, H., et al. (2005) · PubMed · Cited by 35 · see citing works
Mode of DNA binding of cis-platinum(II) antitumor drugs: a base sequence-dependent mechanism is proposed.
Kelman, A. D., & Peresie, H. J. (1980) · PubMed · Cited by 35 · see citing works
Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance
Janson, V., Johansson, A. F., & Grankvist, K. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.54 · Cited by 34 · see citing works
p53 and HER2/neu Expression in Relation to Chemotherapy Response in Patients with Non-Small Cell Lung Cancer
Fijołek, J., Wiatr, E., Rowinska-Zakrzewska, E., Giedronowicz, D., Langfort, R., Chabowski, M., Orlowski, T. M., & Roszkowski, K. (2006) · The International Journal of Biological Markers · doi:10.1177/172460080602100203 · Cited by 33 · see citing works
Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: in situ hybridization study.
Karczmarek-Borowska, B., Filip, A. A., Wojcierowski, J., Smoleń, A., Pilecka, I., & Jabłonka, A. (2005) · PubMed · doi:10.5603/4604 · Cited by 32 · see citing works
Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors
Gaur, S., Chen, L., Yang, L., Wu, X., Un, F., & Yen, Y. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.06.005 · Cited by 29 · see citing works
Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.
Yoshida, M., Khokhar, A. R., & Siddik, Z. H. (1994) · PubMed · Cited by 26 · see citing works
Selectively induced high MRP gene expression in multidrug-resistant human HL60 leukemia cells
Wada, H., Saikawa, Y., Niida, Y., Nishimura, R., Noguchi, T., Matsukawa, H., Ichihara, T., & Koizumi, S. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(98)00027-7 · Cited by 25 · see citing works
XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy
de Pinho, M. B., Costas, F., de Séllos, J., Dienstmann, R., Andrade, P. B., Herchenhorn, D., Peixoto, F. A., Santos, V. O., Small, I. A., Guimarães, D. P., et al. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.03.016 · Cited by 18 · see citing works
A new step ahead for the consideration of ERCC1 as a candidate biomarker to select NSCLC patients for the treatment of cetuximab in combination with cisplatin
Olaussen, K. A. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.20.9785 · Cited by 11 · see citing works

Flagged first, then by citations

3 of the 196 references couldn’t be matched to a known paper.

Sorted by citations

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · see citing works
Self-citation
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,763 · see citing works
Mitochondrial metabolism and cancer
Porporato, P. E., Filigheddu, N., Pedro, J. M. B., Kroemer, G., & Galluzzi, L. (2017) · Cell Research · doi:10.1038/cr.2017.155 · Cited by 1,292 · see citing works
Self-citation
The development of anticancer ruthenium( ii ) complexes: from single molecule compounds to nanomaterials
Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,020 · see citing works
Platinum-based drugs: past, present and future
Dilruba, S., & Kalayda, G. V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2976-z · Cited by 909 · see citing works
Glutaminolysis: A Hallmark of Cancer Metabolism
Yang, L., Venneti, S., & Nagrath, D. (2017) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071516-044546 · Cited by 859 · see citing works
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782 · see citing works
Self-citation
Targeting and delivery of platinum-based anticancer drugs
Wang, X., & Guo, Z. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35259a · Cited by 685 · see citing works
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
Suraweera, A., O'Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 671 · see citing works
Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis
Roh, J.-L., Kim, E. H., Jang, H., & Shin, D. (2017) · Redox Biology · doi:10.1016/j.redox.2016.12.010 · Cited by 662 · see citing works
Synthetic Methods for the Preparation of Platinum Anticancer Complexes
Wilson, J. J., & Lippard, S. J. (2013) · Chemical Reviews · doi:10.1021/cr4004314 · Cited by 631 · see citing works
Therapeutic opportunities within the DNA damage response
Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B., & Pearl, F. M. G. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3891 · Cited by 587 · see citing works
Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma
Shao, H., Chung, J., Lee, K., Balaj, L., Min, C., Carter, B. S., Hochberg, F. H., Breakefield, X. O., Lee, H., & Weissleder, R. (2015) · Nature Communications · doi:10.1038/ncomms7999 · Cited by 613 · see citing works
The Mitochondrial Permeability Transition Pore: Channel Formation by F-ATP Synthase, Integration in Signal Transduction, and Role in Pathophysiology
Bernardi, P., Rasola, A., Forte, M. A., & Lippe, G. (2015) · Physiological Reviews · doi:10.1152/physrev.00001.2015 · Cited by 586 · see citing works
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
Plimack, E. R., Dunbrack, R. L., Brennan, T. A., Andrake, M., Zhou, Y., Serebriiskii, I. G., Slifker, M. J., Alpaugh, K. R., Dulaimi, E., Palma, N. A., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.07.009 · Cited by 521 · see citing works
Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression
Huang, X., Li, Z., Zhang, Q., Wang, W., Li, B., Wang, L., Xu, Z., Zeng, A., Zhang, X., Zhang, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0969-3 · Cited by 478 · see citing works
Tumor glycolysis, an essential sweet tooth of tumor cells
Paul, S., Ghosh, S., & Kumar, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.09.007 · Cited by 449 · see citing works
DNA repair pathways and cisplatin resistance: an intimate relationship
Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B., & Menck, C. F. M. (2018) · Clinics · doi:10.6061/clinics/2018/e478s · Cited by 450 · see citing works
Advances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 442 · see citing works
“Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
Davis, A., Tinker, A. V., & Friedlander, M. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.038 · Cited by 433 · see citing works
Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5
Qin, X., Guo, H.-Y., Wang, X.-N., Zhu, X.-Q., Yan, M., Wang, X., Xu, Q., Shi, J.-B., Lu, E., Chen, W., et al. (2019) · Genome Biology · doi:10.1186/s13059-018-1604-0 · Cited by 386 · see citing works
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
Wang, W., Kryczek, I., Dostál, L., Lin, H., Tan, L., Zhao, L., Lu, F., Wei, S., Maj, T., Peng, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.009 · Cited by 423 · see citing works
Molecular aspects of cancer cell resistance to chemotherapy
Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 409 · see citing works
Molecular mechanisms of cisplatin resistance in cervical cancer
Zhu, X., Zhu, H., Luo, H., Zhang, W., Shen, Z., & Hu, X. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s106412 · Cited by 408 · see citing works
EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer
Haslehurst, A., Koti, M., Dharsee, M., Nuin, P. A. S., Evans, K., Geraci, J., Childs, T. J., Chen, J., Li, J., Weberpals, J. I., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-91 · Cited by 402 · see citing works
DNA repair mechanisms in cancer development and therapy
Torgovnick, A., & Schumacher, B. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00157 · Cited by 403 · see citing works
Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
Tchounwou, P. B., Dasari, S. R., Noubissi, F. K., Ray, P. C., & Kumar, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267383 · Cited by 401 · see citing works
Combinatorial Strategies for the Induction of Immunogenic Cell Death
Bezu, L., Gomes-da-Silva, L. C., Dewitte, H., Breckpot, K., Fucikova, J. P., Špíšek, R., Galluzzi, L., Kepp, O., & Kroemer, G. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00187 · Cited by 389 · see citing works
Self-citation
Molecular mechanisms of chemo‐ and radiotherapy resistance and the potential implications for cancer treatment
Liu, Y., Zheng, C., Huang, Y., He, M., Xu, W. W., & Li, B. (2021) · MedComm · doi:10.1002/mco2.55 · Cited by 392 · see citing works
Cisplatin in cancer treatment
Romani, A. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115323 · Cited by 390 · see citing works
The Fanconi Anemia Pathway in Cancer
Joshi, N., Färkkilä, A., & D’Andrea, A. D. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050422 · Cited by 373 · see citing works
Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer
Roh, J., Kim, E. H., Jang, H. J., Park, J. Y., & Shin, D. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.035 · Cited by 375 · see citing works
Copper metabolism as a unique vulnerability in cancer
Shanbhag, V., Gudekar, N., Jasmer, K. J., Papageorgiou, C., Singh, K. D., & Petris, M. J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118893 · Cited by 371 · see citing works
Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin
Aldossary, S. A. (2019) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/1608 · Cited by 368 · see citing works
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
Kim, H., Xu, H., George, E. M., Hallberg, D. L., Kumar, S., Jagannathan, V., Medvedev, S., Kinose, Y., Devins, K. M., Verma, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17127-2 · Cited by 370 · see citing works
YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression
Shi, Y., Fan, S., Wu, M., Zuo, Z., Li, X., Jiang, L., Shen, Q., Xu, P., Zeng, L., Zhou, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12801-6 · Cited by 363 · see citing works
Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition
Bonora, M., Wieckowski, M. R., Chinopoulos, C., Kepp, O., Kroemer, G., Galluzzi, L., & Pinton, P. (2015) · Oncogene · doi:10.1038/onc.2014.96 · Cited by 330 · see citing works
Self-citation
Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma
Shi, Y., Lim, S. K., Liang, Q., Iyer, S. V., Wang, H.-Y., Wang, Z., Xie, X., Sun, D., Chen, Y.-J., Tabar, V., et al. (2019) · Nature · doi:10.1038/s41586-019-0993-x · Cited by 325 · see citing works
Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells
Tan, Y., Li, J., Zhao, G., Huang, K., Cárdenas, H., Wang, Y., Matei, D. E., & Cheng, J. (2022) · Nature Communications · doi:10.1038/s41467-022-32101-w · Cited by 317 · see citing works
Metal-based drugs that break the rules
Allardyce, C. S., & Dyson, P. J. (2016) · Dalton Transactions · doi:10.1039/c5dt03919c · Cited by 309 · see citing works
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Pol, J. G., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Sautès‐Fridman, C., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008866 · Cited by 306 · see citing works
Self-citation
Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium
Konkankit, C. C., Marker, S. C., Knopf, K. M., & Wilson, J. J. (2018) · Dalton Transactions · doi:10.1039/c8dt01858h · Cited by 285 · see citing works
The Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272 · see citing works
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Garg, A. D., More, S., Rufo, N., Meçe, O., Sassano, M. L., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386829 · Cited by 277 · see citing works
Self-citation
Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance
Takahashi, N., Chen, H., Harris, I. S., Stover, D. G., Selfors, L. M., Bronson, R. T., Raedt, T. D., Cichowski, K. M., Welm, A. L., Mori, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.001 · Cited by 277 · see citing works
Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets
Liu, R., Wu, J., Guo, H., Yao, W., Li, S., Lu, Y., Jia, Y., Liang, X., Tang, J., & Zhang, H. (2023) · MedComm · doi:10.1002/mco2.292 · Cited by 287 · see citing works
Trial watch
Vacchelli, E., Senovilla, L., Eggermont, A. M. M., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 265 · see citing works
Self-citation
Cytosolic DNA Sensing in Organismal Tumor Control
Vanpouille-Box, C., Demaria, S., Formenti, S. C., & Galluzzi, L. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.013 · Cited by 250 · see citing works
Self-citation
The state-of-play and future of platinum drugs
Apps, M. G., Choi, E. H. Y., & Wheate, N. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0237 · Cited by 256 · see citing works
Trial watch
Vacchelli, E., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255 · see citing works
Self-citation
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259 · see citing works
METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy
Sun, Y., Shen, W., Hu, S., Lyu, Q., Wang, Q., Wei, T., Zhu, W., & Zhang, J. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02638-9 · Cited by 256 · see citing works
Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles
Rossi, A., & Maïo, M. D. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1170596 · Cited by 246 · see citing works
Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer
Li, L., He, D., Guo, Q., Zhang, Z., Ru, D., Wang, L., Gong, K., Liu, F., Duan, Y., & He, L. N. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01264-5 · Cited by 232 · see citing works
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., Ruysscher, D. D., Tejpar, S., Vandenberghe, P., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 226 · see citing works
Self-citation
Chloroquine and hydroxychloroquine for cancer therapy
Manic, G., Obrist, F., Kroemer, G., Vitale, I., & Galluzzi, L. (2014) · Molecular & Cellular Oncology · doi:10.4161/mco.29911 · Cited by 223 · see citing works
Self-citation
Combating the Drug Resistance of Cisplatin Using a Platinum Prodrug Based Delivery System
Min, Y., Mao, C., Chen, S., Ma, G., Wang, J., & Liu, Y. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201562 · Cited by 223 · see citing works
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine
Hiley, C. T., de Bruin, E. C., McGranahan, N., & Swanton, C. (2014) · Genome biology · doi:10.1186/s13059-014-0453-8 · Cited by 221 · see citing works
Linking the future of anticancer metal-complexes to the therapy of tumour metastases
Bergamo, A., & Sava, G. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00134j · Cited by 220 · see citing works
The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells
Pink, R. C., Samuel, P., Massa, D., Caley, D. P., Brooks, S. A., & Carter, D. R. F. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.12.042 · Cited by 218 · see citing works
miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2
An, Y., Zhang, Z., Shang, Y., Jiang, X., Dong, J., Yu, P., Nie, Y., & Zhao, Q. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.123 · Cited by 218 · see citing works
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
Petroni, G., Cantley, L. C., Santambrogio, L., Formenti, S. C., & Galluzzi, L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00579-w · Cited by 215 · see citing works
Self-citation
Glutathione-Scavenging Poly(disulfide amide) Nanoparticles for the Effective Delivery of Pt(IV) Prodrugs and Reversal of Cisplatin Resistance
Ling, X., Chen, X., Riddell, I. A., Tao, W., Wang, J., Hollett, G., Lippard, S. J., Farokhzad, O. C., Shi, J., & Wu, J. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01924 · Cited by 209 · see citing works
Light-activatable liposomes for repetitive on-demand drug release and immunopotentiation in hypoxic tumor therapy
Yang, Y., Liu, X., Ma, W., Xu, Q., Chen, G., Wang, Y., Xiao, H., Li, N., Liang, X., Yu, M., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120456 · Cited by 211 · see citing works
Basic Mechanisms of Therapeutic Resistance to Radiation and Chemotherapy in Lung Cancer
Willers, H., Azzoli, C. G., Santivasi, W. L., & Xia, F. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e318292e4e3 · Cited by 209 · see citing works
Development of liposomal formulations: From concept to clinical investigations
Fan, Y., & Zhang, Q. (2013) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2013.07.010 · Cited by 207 · see citing works
Therapeutic strategies to overcome cisplatin resistance in ovarian cancer
Song, M., Cui, M., & Liu, K. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114205 · Cited by 207 · see citing works
Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II
Molinaro, C., Martoriati, A., Pélinski, L., & Cailliau, K. (2020) · Cancers · doi:10.3390/cancers12102863 · Cited by 200 · see citing works
Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer
Zhang, K., Erkan, E. P., Jamalzadeh, S., Dai, J., Andersson, N., Kaipio, K., Lamminen, T., Mansuri, N., Huhtinen, K., Carpén, O., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm1831 · Cited by 196 · see citing works
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition
Cruz‐Bermúdez, A., Briviesca, R. L., Vicente-Blanco, R. J., García‐Grande, A., Coronado, M. J., Laine-Menéndez, S., Palacios-Zambrano, S., Moreno-Villa, M. R., Ruiz-Valdepeñas, A. M., Lendinez, C., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.03.009 · Cited by 196 · see citing works
Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis
Li, F., Liu, J., Bao, R., Yan, G., Feng, X., Xu, Y., Sun, Y., Yan, W., Ling, Z., Xiong, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02950-5 · Cited by 197 · see citing works
In Vitro Anticancer Activity and in Vivo Biodistribution of Rhenium(I) Tricarbonyl Aqua Complexes
Knopf, K. M., Murphy, B. L., MacMillan, S. N., Baskin, J. M., Barr, M. P., Boros, E., & Wilson, J. J. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08640 · Cited by 193 · see citing works
USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy
García‐Santisteban, I., Peters, G. J., Giovannetti, E., & Rodríguez, J. A. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-91 · Cited by 191 · see citing works
Emerging role of NRF2 in ROS-mediated tumor chemoresistance
Xue, D., Zhou, X., & Qiu, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110676 · Cited by 191 · see citing works
miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1
Shang, Y., Zhang, Z., Liu, Z., Feng, B., Ren, G., Li, K.-J., Zhou, L., Sun, Y., Li, M., Zhou, J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.297 · Cited by 189 · see citing works
Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics
Wijdeven, R. H. M., Pang, B., Assaraf, Y. G., & Neefjes, J. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.07.001 · Cited by 186 · see citing works
Precision medicine in head and neck cancer.
Kaidar-Person, O., Gil, Z., & Billan, S. (2018) · Drug resistance updates · doi:10.1016/j.drup.2018.09.001 · Cited by 169 · see citing works
Phorbiplatin, a Highly Potent Pt(IV) Antitumor Prodrug That Can Be Controllably Activated by Red Light
Wang, Z., Wang, N., Cheng, S., Xu, K., Deng, Z., Chen, S., Xu, Z., Xie, K., Tse, M., Shi, P., et al. (2019) · Chem · doi:10.1016/j.chempr.2019.08.021 · Cited by 186 · see citing works
Collagen VI disorders: Insights on form and function in the extracellular matrix and beyond
Lamandé, S. R., & Bateman, J. F. (2017) · Matrix Biology · doi:10.1016/j.matbio.2017.12.008 · Cited by 185 · see citing works
Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies
Callejo, À., Sedó-Cabezón, L., Juan, I. D., & Llorens, J. (2015) · Toxics · doi:10.3390/toxics3030268 · Cited by 184 · see citing works
Upregulation of programmed cell death ligand 1 promotes resistance response in non‐small‐cell lung cancer patients treated with neo‐adjuvant chemotherapy
Zhang, P., Ma, Y., Lv, C., Huang, M., Li, M., Dong, B., Liu, X., An, G., Zhang, W., Zhang, J., et al. (2016) · Cancer Science · doi:10.1111/cas.13072 · Cited by 182 · see citing works
The role of ABC transporters in ovarian cancer progression and chemoresistance
Ween, M. P., Armstrong, M., Oehler, M. K., & Ricciardelli, C. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.05.012 · Cited by 182 · see citing works
Combating the Drug Resistance of Cisplatin Using a Platinum Prodrug Based Delivery System
Min, Y., Mao, C., Chen, S., Ma, G., Wang, J., & Liu, Y. (2012) · Angewandte Chemie · doi:10.1002/ange.201201562 · Cited by 182 · see citing works
Antioxidant Intake and Antitumor Therapy: Toward Nutritional Recommendations for Optimal Results
Mut‐Salud, N., Alvarez, P. J., Garrido, J. M., Carrasco, E., Aránega, A., & Rodríguez‐Serrano, F. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/6719534 · Cited by 180 · see citing works
Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs
Xu, Z., Wang, Z., Deng, Z., & Zhu, G. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.213991 · Cited by 180 · see citing works
Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy
He, J., Yu, J.-J., Xu, Q., Wang, L., Zheng, J. Z., Liu, L.-Z., & Jiang, B. (2015) · Autophagy · doi:10.1080/15548627.2015.1009781 · Cited by 179 · see citing works
Cisplatin Resistance Associated with PARP Hyperactivation
Michels, J., Vitale, I., Galluzzi, L., Adam, J., Olaussen, K. A., Kepp, O., Senovilla, L., Talhaoui, I., Guegan, J., Enot, D. P., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3000 · Cited by 176 · see citing works
Self-citation
Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis
Zhu, Z., Du, S., Du, Y., Ren, J., Ying, G., & Zhao, Y. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14250 · Cited by 176 · see citing works
NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells
Jiang, P., Wu, X., Xuemin, W., Huang, W., & Feng, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.9712 · Cited by 174 · see citing works
Mitochondrial Transfer in Cancer: A Comprehensive Review
Zampieri, L. X., Silva‐Almeida, C., Rondeau, J. D., & Sonveaux, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063245 · Cited by 173 · see citing works
Polymer encapsulation of ruthenium complexes for biological and medicinal applications
Villemin, E., Ong, Y. C., Thomas, C. M., & Gasser, G. (2019) · Nature Reviews Chemistry · doi:10.1038/s41570-019-0088-0 · Cited by 170 · see citing works
Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives
Pujade-Lauraine, É., Banerjee, S. N., & Pignata, S. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00194 · Cited by 170 · see citing works
ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer
Nie, S., Zhang, L., Liu, J., Wan, Y., Jiang, Y., Yang, J., Sun, R., Ma, X., Sun, G., Meng, H., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02088-1 · Cited by 170 · see citing works
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Jurkovičová, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314672 · Cited by 170 · see citing works
Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
Nogales, V., Reinhold, W. C., Varma, S., Martínez‐Cardús, A., Moutinho, C., Morán, S., Heyn, H., Sebio, A., Barnadas, A., Pommier, Y. G., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6413 · Cited by 169 · see citing works
Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest
Sarin, N., Engel, F., Kalayda, G. V., Mannewitz, M., Cinatl, J. J., Rothweiler, F., Michaelis, M., Saafan, H., Ritter, C. A., Jaehde, U., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181081 · Cited by 169 · see citing works
Pro-survival autophagy and cancer cell resistance to therapy
Das, C. K., Mandal, M., & Kögel, D. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9727-z · Cited by 169 · see citing works
Advancement of metal compounds as therapeutic and diagnostic metallodrugs: Current frontiers and future perspectives
Yousuf, I., Bashir, M., Arjmand, F., & Tabassum, S. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214104 · Cited by 167 · see citing works
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo
Rocha, C. R. R., Garcia, C. C. M., Vieira, D. B., Quinet, A., de Andrade-Lima, L. C., Munford, V., Belizário, J. E., & Menck, C. F. M. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.465 · Cited by 163 · see citing works
Investigation into antiproliferative activity and apoptosis mechanism of new arene Ru( ii ) carbazole-based hydrazone complexes
Kamatchi, T. S., Subarkhan, M. K. M., Ramesh, R., Wang, H., & Małecki, J. G. (2020) · Dalton Transactions · doi:10.1039/d0dt01476a · Cited by 165 · see citing works

Authors: Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G.
Affiliations: Inserm (FR)
Université Paris-Sud (FR)
Corresponding author: Kroemer, G
ORCID: Galluzzi, L
Senovilla, L
Vitale, I
Michels, J
Martins, I
Kepp, O
Castedo, M
Kroemer, G
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2011-09-05
Volume: 31
Issue: 15
Pages: 1869-1883
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/onc.2011.384
OpenAlex: W2141037581
Cited by: 2,760
References: 196
Citations by year: 2026: 154 · 2025: 187 · 2024: 244 · 2023: 220 · 2022: 247 · 2021: 308 · 2020: 252 · 2019: 213 · 2018: 169 · 2017: 167 · 2016: 159 · 2015: 160 · 2014: 145 · 2013: 89 · 2012: 44
FWCI: 7.83
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Funders: European Commission
Ligue Contre le Cancer
Fondation Bettencourt Schueller
Labex Immuno-Oncology
Topics: Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords: cisplatin resistance, chemoresistance, platinum anticancer drugs, DNA damage response, mitochondrial apoptosis, chemosensitization, DNA lesions
MeSH terms: Cisplatin, DNA Damage, DNA Repair, Humans, Signal Transduction, DNA Adducts, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Molecular mechanisms of cisplatin resistance

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks